FEB 20, 2017 10:19 AM PST

Scalp-cooling Device Gets Thumbs Up from 2 US Studies

WRITTEN BY: Xuan Pham

Although the scalp-cooling cap has been available in Europe for a number of years, the device was only approved in the US market in 2015. Now, independent results by two notable institutions in the US provide supporting evidence that the device reduces hair loss in patients undergoing chemotherapy.

Traditional cancer treatment with chemotherapy involves using highly toxic drugs to kill errant cancer cells. Because the majority of these drugs do not discriminate between cancer and normal cells, patients experience collateral damages as adverse side effects. Hair loss (alopecia) is a common side effect of certain types of chemotherapy, typically associated with treatment for breast cancer. Though considered a temporary effect, minimizing hair loss is important to the quality of life for many patients.

"Some of today's most powerful, life-saving chemotherapy treatments still cause complete hair loss, a side effect that many women consider to be emotionally devastating," said Dr. Hope Rugo, Principal Investigator for the study and Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center.

Named DigniCap, the cooling system is manufactured by Dignitana in Sweden. It works by circulating a liquid coolant to a tight-fitting silicone cap worn on the head during chemotherapy sessions. A second cap made of neoprene covers this cooling cap to act as insulation and prevent loss of cooling. The entire system is computerized with sensors that continuously monitor scalp temperature and allow the system to maintain optimal cooling throughout treatment.

The coldness of the cap acts to constrict blood vessels in the scalp, reducing blood flow to the hair follicles and protecting the hair from the flow of toxic chemotherapy agents in the body. In addition, the cooling action slows down cell division activities of the hair follicles, which makes them less susceptible to the uptake of chemotherapy drugs. These factors together reduce the risk of hair loss associated with cancer treatment.

A U.S. clinical trial studied the effects of the DigniCap in 122 women with Stage I and Stage II breast cancer who were undergoing chemotherapy. Patients then self-assessed the hair loss using standardized photographs at one month after the last chemotherapy cycle. More than 66% of these patients reported keeping at least 50% of their hair. In addition, patients reported high satisfaction for the experience: a mean of 87.5 satisfaction with the decision to use the DigniCap, a mean of 70.9 for hair quantity, and a mean of 69.1 for hair quality (ranked from 0 to 100, with 100 being “completely satisfied”). No severe adverse events were reported.

Similarly, another trial, conducted at the Baylor College of Medicine, Houston, researchers found that patients who were not treated with the device were more likely to experience up to 50 percent hair loss.

The US trials only evaluated the device on chemotherapy regimens using taxanes, such as paclitaxel and docetaxel. However, abroad the device has also been studied with anthracyclines, such as epirubicin and doxorubicin.

While the risk of the chemotherapy drug missing breast cancer cells in the scalp is considered extremely low, the benefits of the cooling cap are significant. The device minimizes the psychological impact of the diagnosis and makes the chemotherapy process more tolerable. Reducing hair loss during chemotherapy allows these patients to retain some normalcy and privacy in their lives.

Additional sources: MNT

About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 16, 2022
Cardiology
Height May Be a Risk Factor for Several Conditions
JUN 16, 2022
Height May Be a Risk Factor for Several Conditions
A new study has linked height to a lower risk of coronary heart disease and a higher risk of some circulatory disorders.
JUN 20, 2022
Neuroscience
Brain Lesions Reveal Networks of Addiction
JUN 20, 2022
Brain Lesions Reveal Networks of Addiction
There is no good model for investigating the human brain. A lot of what we know about which parts of the brain perform w ...
JUL 07, 2022
Cancer
Study Suggests Breast Cancer Spreads while Sleeping
JUL 07, 2022
Study Suggests Breast Cancer Spreads while Sleeping
Breast cancer remains the second leading cause of cancer-related death in women in the United States, and experts expect ...
JUL 06, 2022
Technology
New Prosthetic Provides Relief to Diabetic Amputees
JUL 06, 2022
New Prosthetic Provides Relief to Diabetic Amputees
Diabetes is one of the most prominent chronic conditions in the world. In the U.S. alone, diabetes affects about 10% of ...
JUL 30, 2022
Health & Medicine
Large-Scale Study Suggests Link Between Temporary Menstrual Changes and Covid-19 Vaccine
JUL 30, 2022
Large-Scale Study Suggests Link Between Temporary Menstrual Changes and Covid-19 Vaccine
The most comprehensive analysis of menstrual changes following a Covid-19 vaccination has revealed that its recipients e ...
AUG 03, 2022
Cardiology
Cardiovascular diseases could see sharp increase in US by 2060
AUG 03, 2022
Cardiovascular diseases could see sharp increase in US by 2060
In a recent study published in the Journal of the American College of Cardiology, a collaborative research team from the ...
Loading Comments...